MY ACCOUNT | NEWSLETTER |

Serum symmetric dimethylarginine concentration in healthy neonatal foals

SDMA cannot be used as a marker of renal dysfunction in this age group


Symmetric dimethylarginine (SDMA) is widely used in other species as a marker of renal dysfunction and is considered a more sensitive indicator of glomerular filtration rate than creatinine. Reference ranges are established in healthy adult horses (≤14 μg/dL) and concentrations are increased in horses with acute kidney injury (median 32 μg/dL; range 15-92).

To establish the normal range of SDMA concentrations in neonatal Thoroughbreds.

Blood samples were collected from Thoroughbred foals <36 hours old deemed healthy by physical examination. Exclusion criteria included foals from mares undergoing treatment for placentitis and foals that developed clinical disease or died/euthanased <2 weeks from birth. Biochemistry and serum SDMA concentrations were obtained.

Subjects included 120 foals. Median age was 13.5 hours (range 1.0-34.0). Median and 95% confidence interval for SDMA concentration was 69.0 µg/dL (63.0, 75.0; range 35.0-376.0). A cut-off value of 168 µg/dL would include 95% of individuals and is therefore suggested. Serum SDMA concentration was correlated with age (R= -0.3, P = 0.003), creatinine concentration (R = 0.6, P = <0.001) and urea concentration (R = 0.3, P = 0.002).

Limitations include a small sample size, no consideration of subclinical disease and a short follow-up period.

In equine neonates, SDMA concentration is higher than in adult horses, older foals and adults with acute kidney injury. Therefore, currently SDMA cannot be used as a marker of renal dysfunction in this age group. Further work is required to assess whether SDMA concentration is increased in neonates with renal disease and, if so, what cut-off should be used.


“Serum symmetric dimethylarginine concentration in healthy neonatal Thoroughbred foals”. Rachel L Gough, Kate F McGovern. Equine Vet J. 2021 Oct 4.  doi: 10.1111/evj.13520.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Advancing the 3Rs: innovation, implementation, ethics and society

Like0
Dislike0

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Like0
Dislike0

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Like0
Dislike0

One Committed and Caring NC State Veterinary Student, So Many Choices

Like0
Dislike0

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top